Separate terms with OR to return results that match either term.
 
Clear All
9,715 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) (Ascending) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
63304-0096-30 63304-0096 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 In Use
63304-0135-11 63304-0135 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 In Use
63304-0135-30 63304-0135 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 In Use
63304-0158-01 63304-0158 Bromocriptine Mesylate Bromocriptine Mesylate 5.0 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Dec. 22, 2016 In Use
63304-0158-30 63304-0158 Bromocriptine Mesylate Bromocriptine Mesylate 5.0 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Dec. 22, 2016 In Use
63304-0346-05 63304-0346 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 10, 2012 In Use
63304-0346-11 63304-0346 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 10, 2012 In Use
63304-0346-30 63304-0346 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 10, 2012 In Use
63304-0346-69 63304-0346 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 10, 2012 In Use
63304-0347-05 63304-0347 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 10, 2012 In Use

Found 9,715 results in 17 milliseconds — Export these results